-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA Biotechnology To Present New Phase 2 Clinical Trial Data At The H.C. Wainwright 26th Annual Global Investment Conference, Updates From THIO-101 To Include Response Rates And Survival Follow-Up

Benzinga·09/04/2024 12:34:23
Listen to the news
  • Updates from THIO-101 to include response rates and survival follow-up

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City.

Dr. Vitoc's presentation will reveal the latest clinical data from MAIA's Phase 2 THIO-101 clinical trial of lead candidate THIO sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who failed 2 or more standard-of-care therapy regimens.